Avon
This article was originally published in The Rose Sheet
Executive Summary
Direct-seller remains confident business will reach $8.5 bil. by 2007 with 20% operating margin, Exec VP-Asia Pacific, Europe, Middle East & Africa Robert Toth reports during Merrill Lynch Global Branded Consumer Products Conference Oct. 1. Exec says Avon will focus on Central and Eastern Europe as key areas to contribute to growth, highlights Russia as the biggest opportunity in the group. Firm recently announced plans to open $40 mil. manufacturing facility outside Moscow in mid-2004 (1"The Rose Sheet" Sept. 29, 2003, In Brief). Other nations Avon views as strategic regional opportunities include Turkey, Kazakhstan and Bosnia, Toth says...
You may also be interested in...
Avon
Direct-seller begins construction on $40 mil. manufacturing facility near Narofominsk, Russia to support firm's beauty business in the region. Russia is one of Avon's fastest growing markets, with sales expected to reach $500 mil. in 2007, firm says. The 250,000 square foot facility, expected to open in mid-2004, will employ over 800 workers and produce 185 mil. units of cosmetic products, Avon says. Items manufactured at the plant will be sold in Russia through Avon's 194,000 consultants, and in Ukraine and Kazakhstan. Avon has had a presence in Russia since 1995, with regional sales of $142 mil. in 2002...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.